SA PRO
Free Account
Enliven Therapeutics, Inc.ELVNNASDAQ
LOADING
|||
OverviewChartsNewsFundamentalsEarningsAnalysts

Analyst Sentiment

Analysts lean bullish — 100% recommend buying.

Consensus Rating
Buy
5 analysts·Limited coverage
100%
Rating Distribution
Strong Buy
00%
Buy
5100%
Hold
00%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 54% higher.

Bear Case
$39.00
+38%
Consensus
$43.33
+54%
Bull Case
$52.00
+85%
Price Range5 analysts
Low
Consensus
High
$39.00
$52.00
Current Target
Current Price
$28.17
Upside to Target
$15.16

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Earnings Surprises

Recent Analyst Actions

Jun 16, 2025Robert W. Baird
Enliven price target raised to $52 from $40 at Baird
Target:$52.00
+125.2%from $23.09
Mar 21, 2025H.C. Wainwright
Enliven price target raised to $39 from $37 at H.C. Wainwright
Target:$39.00
+85.0%from $21.08
Nov 15, 2024Robert W. Baird
Enliven Therapeutics (ELVN) PT Raised to $40 at Baird
Target:$40.00
+66.3%from $24.05
Sep 23, 2024Mizuho Securities
Mizuho Reiterates Outperform Rating on Enliven Therapeutics (ELVN)
Target:$39.00
+63.9%from $23.80
Jun 10, 2024Robert W. Baird
Baird Starts Enliven Therapeutics (ELVN) at Outperform
Target:$32.00
+41.7%from $22.58
Apr 9, 2024Mizuho Securities
Mizuho Starts Enliven Therapeutics (ELVN) at Buy
Target:$34.00
+85.8%from $18.30

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance